Kamel Laribi

1.0k total citations
6 papers, 247 citations indexed

About

Kamel Laribi is a scholar working on Pathology and Forensic Medicine, Genetics and Dermatology. According to data from OpenAlex, Kamel Laribi has authored 6 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 3 papers in Genetics and 2 papers in Dermatology. Recurrent topics in Kamel Laribi's work include Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and CAR-T cell therapy research (2 papers). Kamel Laribi is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and CAR-T cell therapy research (2 papers). Kamel Laribi collaborates with scholars based in France, Spain and United States. Kamel Laribi's co-authors include Loïc Ysebaert, Ronan Le Calloch, Laëtitia Souchet, Brigitte Dreyfus, Caroline Dartigeas, David Ghez, K. Delavigne, Charles Herbaux, Marion Malphettes and Franciane Paul and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Pharmacokinetics.

In The Last Decade

Kamel Laribi

5 papers receiving 246 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kamel Laribi France	4	143	92	77	77	77	6	247
Laëtitia Souchet France	6	153 1.1×	107 1.2×	93 1.2×	98 1.3×	96 1.2×	19	304
Tilly Varughese United States	3	121 0.8×	78 0.8×	70 0.9×	78 1.0×	68 0.9×	5	211
Sushrut Patil Australia	10	61 0.4×	60 0.7×	78 1.0×	81 1.1×	37 0.5×	35	292
Ahmad Al Jijakli France	5	62 0.4×	62 0.7×	69 0.9×	72 0.9×	195 2.5×	11	344
Georgios Pongas United States	10	52 0.4×	88 1.0×	136 1.8×	140 1.8×	35 0.5×	26	334
Daniela Vallerini Italy	9	49 0.3×	43 0.5×	53 0.7×	96 1.2×	58 0.8×	15	233
Davide Rapezzi Italy	7	41 0.3×	49 0.5×	75 1.0×	97 1.3×	33 0.4×	8	203
Karin S. Ku United States	8	48 0.3×	37 0.4×	79 1.0×	110 1.4×	19 0.2×	9	232
Marina Popova Russia	8	25 0.2×	86 0.9×	100 1.3×	79 1.0×	33 0.4×	61	238
Anne‐Claire Mamez Switzerland	10	28 0.2×	40 0.4×	128 1.7×	153 2.0×	56 0.7×	39	353

Countries citing papers authored by Kamel Laribi

Since Specialization

Citations

This map shows the geographic impact of Kamel Laribi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamel Laribi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamel Laribi more than expected).

Fields of papers citing papers by Kamel Laribi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamel Laribi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamel Laribi. The network helps show where Kamel Laribi may publish in the future.

Co-authorship network of co-authors of Kamel Laribi

This figure shows the co-authorship network connecting the top 25 collaborators of Kamel Laribi. A scholar is included among the top collaborators of Kamel Laribi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamel Laribi. Kamel Laribi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Bartlett, Nancy L., Uwe Hahn, Won Seog Kim, et al.. (2025). Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. 43(9). 1061–1072. 7 indexed citations

2.

Bartlett, Nancy L., Uwe Hahn, Won Seog Kim, et al.. (2025). Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma. Future Oncology. 21(16). 1965–1983.

3.

Laribi, Kamel, Bernard Bégaud, Arnaud Pigneux, et al.. (2020). Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase. British Journal of Clinical Pharmacology. 86(5). 991–998. 11 indexed citations

4.

Ghez, David, Caroline Protin, Marine Baron, et al.. (2018). Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 131(17). 1955–1959. 205 indexed citations

5.

Nowakowski, Grzegorz S., David Belada, Kateřina Kopečková, et al.. (2017). B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase II/III trial.. Journal of Clinical Oncology. 35(15_suppl). TPS7571–TPS7571. 2 indexed citations

6.

Gagez, Anne-Laure, Stéphane Leprêtre, Valérie Gouilleux‐Gruart, et al.. (2016). Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics. 56(6). 635–647. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact